Health Care [ 11/12 ] | Health Care Equipment & Supplies [ 53/75 ]
NASDAQ | Common Stock
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer.
The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma.
The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers.
TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 1, 24 | -1.56 Decreased by -15.50 K% | -0.69 Decreased by -126.09% |
| Nov 14, 23 | -0.13 Decreased by -762.00% | - |
| Aug 30, 23 | -0.12 Decreased by -254.13% | - |
| Mar 31, 23 | -0.05 Decreased by -160.67% | - |
| Mar 22, 23 | -0.01 Decreased by -111.11% | - |
| Nov 10, 22 | 0.02 Decreased by -66.67% | - |
| Aug 10, 22 | 0.08 Increased by +700.00% | - |
| May 11, 22 | 0.09 Increased by +1000.00% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 5.19 M Increased by +32.37% | -1.29 M Increased by +84.11% | Decreased by -24.76% Increased by +88.00% |
| Jun 30, 23 | 4.61 M Increased by +N/A% | -13.97 M Decreased by -685.61% | Decreased by -302.99% - |
| Mar 31, 23 | 2.98 M Increased by +25.91% | -8.27 M Decreased by -5.02% | Decreased by -277.08% Increased by +16.59% |
| Dec 31, 22 | 3.23 M Increased by +N/A% | -22.54 M Decreased by -878.46% | Decreased by -698.76% - |
| Sep 30, 22 | 3.92 M Increased by +N/A% | -8.09 M Decreased by -7.59 K% | Decreased by -206.30% - |
| Jun 30, 22 | N/A Decreased by N/A% | 2.39 M Increased by +529.84% | - - |
| Mar 31, 22 | 2.37 M Increased by +N/A% | -7.87 M Decreased by -2.02 K% | Decreased by -332.19% - |
| Dec 31, 21 | N/A - | 2.90 M - | - - |